Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of -51.01% is in line with its 4-year average of -54.27%, around the middle of its 4-year range (-76.43%–-23.57%).
As of the fiscal period ended Tuesday, June 30, 2026. 10.82% above its 12-month average of -57.19%.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -51.01%.
RETURN ON INVESTED CAPITAL (ROIC)
-51.01%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
-57.19%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
-61.81%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
+10.82%
CURRENT VS 3Y AVG
+17.48%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-27.19%
median of 428 covered companies
CURRENT VS SECTOR MEDIAN
-87.59%
vs the sector median at left
AN2 Therapeutics, Inc.
Market Cap
$202.05M
Return on Invested Capital (ROIC)
-51.01%
TTM Avg
-57.19%
3Y Avg
-61.81%
5Y Avg
N/A
Market Cap
$206.61M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$192.97M
Return on Invested Capital (ROIC)
-74.02%
TTM Avg
-48.91%
3Y Avg
-62.69%
5Y Avg
-47.07%
Market Cap
$218.42M
Return on Invested Capital (ROIC)
26.14%
TTM Avg
3.79%
3Y Avg
-12.27%
5Y Avg
-17.37%
Market Cap
$184.12M
Return on Invested Capital (ROIC)
-5.22%
TTM Avg
-22.12%
3Y Avg
-29.09%
5Y Avg
-27.39%
Market Cap
$220.94M
Return on Invested Capital (ROIC)
-71.04%
TTM Avg
-53.65%
3Y Avg
-40.34%
5Y Avg
-35.55%
Market Cap
$179.70M
Return on Invested Capital (ROIC)
-9.57%
TTM Avg
-477.38%
3Y Avg
-295.61%
5Y Avg
-295.61%
Market Cap
$176.96M
Return on Invested Capital (ROIC)
-1039.56%
TTM Avg
-137.05%
3Y Avg
-111.74%
5Y Avg
-93.55%
Market Cap
$174.17M
Return on Invested Capital (ROIC)
-30.23%
TTM Avg
-28.70%
3Y Avg
-31.34%
5Y Avg
-41.69%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | $202.05M | -51.01% | -57.19% | -61.81% | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $206.61M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.97M | -74.02% | -48.91% | -62.69% | -47.07% |
| Compugen Ltd. (CGEN)vs › | $218.42M | 26.14% | 3.79% | -12.27% | -17.37% |
| Journey Medical Corporation (DERM)vs › | $184.12M | -5.22% | -22.12% | -29.09% | -27.39% |
| Alector, Inc. (ALEC)vs › | $220.94M | -71.04% | -53.65% | -40.34% | -35.55% |
| Canton Strategic Holdings Inc (CNTN)vs › | $179.70M | -9.57% | -477.38% | -295.61% | -295.61% |
| Cue Biopharma, Inc. (CUE)vs › | $176.96M | -1039.56% | -137.05% | -111.74% | -93.55% |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | -30.23% | -28.70% | -31.34% | -41.69% |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | -135.38% | -110.80% | -91.23% | -65.73% |
ROIC
-51.0%
ROE
-47.8%
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2026-06-30 | -51.01% |
| 2026-03-31 | -45.31% |
| 2025-12-31 | -71.59% |
| 2025-09-30 | -61.93% |
| 2025-06-30 | -56.12% |
| 2025-03-31 | -68.23% |
| 2024-12-31 | -69.38% |
| 2024-09-30 | -76.43% |
| 2024-06-30 | -72.36% |
| 2024-03-31 | -65.00% |
| 2023-12-31 | -55.84% |
| 2023-09-30 | -45.55% |
| 2023-06-30 | -64.82% |
| 2023-03-31 | -61.34% |
| 2022-12-31 | -44.31% |
| 2022-09-30 | -35.41% |
| 2022-06-30 | -28.09% |
| 2022-03-31 | -23.57% |
| 2021-12-31 | -34.84% |
